LB Pharmaceuticals Q2 net loss widens on higher R&D costs

LB Pharmaceuticals

11/08/2026 13:10

Overview
US neuromedicines developer's Q2 net loss widened, driven by higher R&D expenses
Company raised $150 mln in private placement to fund pipeline expansion
Cash position expected to fund operations beyond Q2 2029

Outlook
LB Pharmaceuticals expects topline data from Phase 3 NOVA-2 trial in schizophrenia in H1 2027
Company anticipates topline data from Phase 2 trial in bipolar depression in Q1 2028
Company expects current cash to fund operations beyond Q2 2029

Result Drivers
CLINICAL TRIAL COSTS - Company said higher R&D expenses were mainly due to increased spending on Phase 3 clinical trial of LB-102 in acute schizophrenia
PIPELINE DEVELOPMENT - Additional R&D spending driven by Phase 2 trial in bipolar depression, drug formulation, and preclinical work
PERSONNEL AND COMPENSATION - Higher personnel-related and stock-based compensation expenses contributed to increased operating costs

Company press release: ID:nGNX6Zlw2L

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$51.60 mln
 
Q2 Loss Per Basic Share
 
$1.71
 
Q2 Pretax Loss
 
$51.60 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for LB Pharmaceuticals Inc is $45.00, about 1.9% below its August 10 closing price of $45.85

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - CervoMed Q2 net loss lower than estimates as costs drop
Aug 11 - Neurogene Q2 adjusted loss per share misses estimates on employee costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)